Trial · NCT06607016
A Clinical Trial With KJ103 in Anti-GBM Disease
NCT06607016, Phase 2, Active not recruiting, Shanghai Bao Pharmaceuticals Co., Ltd.
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Clinical Trial With KJ103 in Anti-GBM Disease. Trials, record NCT06607016. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06607016
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Clinical Trial With KJ103 in Anti-GBM Disease
- NCT number
- NCT06607016
- Status
- Active not recruiting
- Phases
- Phase 2
- Enrollment
- 12 participants, estimated
- Lead sponsor
- Shanghai Bao Pharmaceuticals Co., Ltd.
- Conditions
- Anti-Glomerular Basement Membrane Disease
- Interventions
- KJ103 for Injection, Cyclophosphamide, Glucocorticoids, Plasma exchange (PE)
- First posted
- 2024-09-23
- Last updated
- 2025-06-13
Source ClinicalTrials.gov
Registered outcomes13
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Renal function | day 90, day 180 | Proportion of subjects with renal function after KJ103 administration. |
| Secondary | Adverse events | day 180 | Assessing the incidence and severity of adverse events (AEs) and serious adverse events (SAEs) via the Common Terminology Criteria for Adverse Events (CTCAE) v5.0. |
| Secondary | Proportion and number of subjects requiring PE | day 180 | Proportion and number of subjects requiring PE after KJ103 administration. |
| Secondary | Anti-GBM antibodies | day 180 | Number of days positive for anti-GBM antibodies after KJ103 administration. |
| Secondary | Immunogenicity | day 180 | Immunogenicity of KJ103 (Anti-KJ103 antibody) in patients with anti-GBM disease. |
| Secondary | eGFR and change from baseline. | Day28, Day60, Day90, Day120, Day150, Day180 | Estimated glomerular filtration rate (eGFR). Glomerular filtration rate is an estimate of the amount of ultrafiltrate produced by each side of the kidney per unit of time and is an indicator of kidney function. |
| Secondary | Pharmacokinetics of KJ103 (Cmax) | day 7 | Maximum observed serum concentration of KJ103 following dosing (Cmax) |
| Secondary | Pharmacokinetics of KJ103 (AUC) | day 7 | Area under the serum concentration versustime curve (AUC) |
| Secondary | Pharmacokinetics of KJ103 (t1/2) | day 7 | Half-life of KJ103 |
| Secondary | Pharmacokinetics of KJ103 (CL) | day 7 | Clearance(CL) is a measure of the ability of the body to clear KJ103 |
1 to 10 of 13Source ClinicalTrials.gov
See all 13 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06607016
GET https://conductscience.org/api/trials/v1/NCT06607016/registered